Achalasia of the esophagus is combination of dysfunction of the lower esophageal sphincter and disorder of the peristaltic movement of the esophageal body. Both components influence one another in a negative way, but the first usually prevails. That is why satisfactory and long-term results can be obtained in most of patients with non-advanced achalasia by Heller's myotomy. In a small group of patients with disease of megaesophagus-type (disorder of the motility of the esophageal body prevails) and in patients in which their disease reach for various reasons the stage of advanced (decompensated) achalasia, the resection-surgery is etiopatogeneticly justified. At the Ist and IInd surgical clinic in Olomouc 331 patients with achalasia have been operated so far. 29 patients treated by resection of a shorter or longer portion of the aboral esophagus, in 2 patients the whole thoracic esophagus was extirpated without thoracotomy. Resection was in principle indicated as secondary treatment. To substitute the esophagus the stomach in various operative modifications was used in two thirds of the patients, in the remaining patients interposition by a segment of the small or large intestine was carried out.

• MeSH
• achalázie jícnu klasifikace   diagnostické zobrazování   chirurgie   MeSH
• lidé MeSH
• následné studie MeSH
• radiografie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH

UNLABELLED: 83 pacemaker (PM)/14 implantable cardioverter-defibrillator (ICD) autopsied patients, predominantly males, deceased 4.0±3.0/2.8±2.5 years after implantation in hospital. Coronary artery disease was most frequent. Its consequences were more severe in ICD patients. Sclerotic and rheumatic heart changes were present in older PM patients group only. The immediate cause of death was mostly of cardiac etiology. Relatively short implant-death interval should be explained by rather great part of non-cardiac causes of death in hospitalised patients. KEYWORDS: pacemakers - implantable cardioverter - defibrillators-causes of death - heart pathology - autopsy.

• Publikační typ
• časopisecké články MeSH

• MeSH
• agregace trombocytů účinky léků   MeSH
• batroxobin * farmakologie   MeSH
• lidé MeSH
• proteasy * MeSH
• trombocytopatie krev   diagnóza   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• batroxobin * MeSH
• proteasy * MeSH

• MeSH
• agregace trombocytů účinky léků   MeSH
• batroxobin farmakologie   MeSH
• lidé MeSH
• proteasy farmakologie   MeSH
• retrakce koagula * MeSH
• trombocyty účinky léků   ultrastruktura   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• batroxobin MeSH
• proteasy MeSH

• MeSH
• batroxobin farmakologie   terapeutické užití   MeSH
• hemokoagulace účinky léků   MeSH
• lidé MeSH
• proteasy farmakologie   MeSH
• tromboflebitida krev   farmakoterapie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• batroxobin MeSH
• proteasy MeSH

• MeSH
• agregace trombocytů účinky léků   MeSH
• batroxobin farmakologie   MeSH
• koagulační faktory fyziologie   MeSH
• lidé MeSH
• proteasy farmakologie   MeSH
• retrakce koagula * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• batroxobin MeSH
• koagulační faktory MeSH
• proteasy MeSH

• MeSH
• batroxobin izolace a purifikace   fyziologie   MeSH
• chromatografie afinitní metody   MeSH
• fibrinogen metabolismus   MeSH
• hadi metabolismus   MeSH
• jedy chřestýšů analýza   metabolismus   MeSH
• sefarosa analogy a deriváty   MeSH
• zvířata MeSH
• Check Tag
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• batroxobin MeSH
• Blue-Sepharose MeSH Prohlížeč
• botrocetin MeSH Prohlížeč
• fibrinogen MeSH
• jedy chřestýšů MeSH
• sefarosa MeSH

• MeSH
• agregace trombocytů účinky léků   MeSH
• AMP cyklický farmakologie   MeSH
• batroxobin antagonisté a inhibitory   MeSH
• hemokoagulace účinky léků   MeSH
• inhibitory proteas * MeSH
• prostaglandiny E farmakologie   MeSH
• retrakce koagula MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• AMP cyklický MeSH
• batroxobin MeSH
• inhibitory proteas * MeSH
• prostaglandiny E MeSH

The aim of this study was to investigate the structure and function of fibrinogen obtained from a patient with normal coagulation times and idiopathic thrombophilia. This was done by SDS-PAGE and DNA sequence analyses, scanning electron microscopy, fibrinopeptide release, fibrin polymerisation initiated by thrombin and reptilase, fibrinolysis, and platelet aggregometry. A novel heterozygous point mutation in the fibrinogen Aα chain, Phe98 to Ile, was found and designated as fibrinogen Vizovice. The mutation, which is located in the RGDF sequence (Aα 95-98) of the fibrinogen coiled-coil region, significantly affected fibrin clot morphology. Namely, the clot formed by fibrinogen Vizovice contained thinner and curled fibrin fibers with reduced length. Lysis of the clots prepared from Vizovice plasma and isolated fibrinogen were found to be impaired. The lysis rate of Vizovice clots was almost four times slower than the lysis rate of control clots. In the presence of platelets agonists the mutant fibrinogen caused increased platelet aggregation. The data obtained show that natural mutation of Phe98 to Ile in the fibrinogen Aα chain influences lateral aggregation of fibrin protofibrils, fibrinolysis, and platelet aggregation. They also suggest that delayed fibrinolysis, together with the abnormal fibrin network morphology and increased platelet aggregation, may be the direct cause of thrombotic complications in the patient associated with pregnancy loss.

• Klíčová slova
• Fibrinogen, RGD sequence, platelet aggregation, pregnancy loss, thrombosis,
• MeSH
• agregace trombocytů MeSH
• batroxobin metabolismus   MeSH
• bodová mutace MeSH
• časové faktory MeSH
• dospělí MeSH
• fibrin metabolismus   MeSH
• fibrinogen genetika   metabolismus   MeSH
• fibrinolýza MeSH
• hemokoagulace MeSH
• heterozygot MeSH
• konformace proteinů MeSH
• lidé MeSH
• samovolný potrat krev   MeSH
• těhotenství MeSH
• trombin metabolismus   MeSH
• trombofilie krev   genetika   MeSH
• vyšetření krevní srážlivosti MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• práce podpořená grantem MeSH
• Názvy látek
• batroxobin MeSH
• fibrin MeSH
• fibrinogen Aalpha MeSH Prohlížeč
• fibrinogen MeSH
• trombin MeSH

BACKGROUND: Both oral ganciclovir and valacyclovir decrease the incidence of cytomegalovirus (CMV) disease after renal transplantation. Moreover, valacyclovir has been shown to reduce the risk of acute rejection. Our study was designed to compare the efficacy and safety of oral ganciclovir and valacyclovir in the prophylaxis of CMV disease after renal transplantation. METHODS: A total of 83 patients were prospectively randomized to 3-month treatment with oral ganciclovir (3 g/day, n=36, GAN) or oral valacyclovir (8 g/day, n=35, VAL). A control group (DEF, n=12) was managed by deferred therapy. RESULTS: No differences were found in demography, immunosuppression, or donor/recipient CMV serology. The 12-month incidence of CMV disease was 67% in the DEF group compared with 6% in the GAN group and 3% in the VAL group (P<0.001 GAN or VAL vs. DEF; P=0.575 GAN vs. VAL). The biopsy-confirmed acute rejection rate at 12 months was 12% in the VAL group compared with 34% in the GAN group (P=0.030) and 58% in the DEF group (P<0.001). The difference between the GAN and DEF groups was not significant (P=0.087). The average CMV-associated costs per patient were $3,072, $2,906, and $4,906 in the GAN, VAL, and DEF groups, respectively. CONCLUSIONS: Valacyclovir and oral ganciclovir are equally effective in the prevention of CMV disease after renal transplantation. Both regimens are cost-effective. Valacyclovir is associated with a significantly reduced risk of acute rejection compared with both ganciclovir prophylaxis and deferred therapy.

• MeSH
• acyklovir škodlivé účinky   analogy a deriváty   terapeutické užití   MeSH
• analýza přežití MeSH
• antivirové látky terapeutické užití   MeSH
• časové faktory MeSH
• cytomegalovirové infekce prevence a kontrola   MeSH
• dospělí MeSH
• ganciklovir škodlivé účinky   terapeutické užití   MeSH
• homologní transplantace MeSH
• imunosupresiva terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nemoci ledvin klasifikace   chirurgie   MeSH
• rejekce štěpu epidemiologie   prevence a kontrola   MeSH
• reoperace MeSH
• rizikové faktory MeSH
• testování histokompatibility MeSH
• transplantace ledvin mortalita   fyziologie   MeSH
• valaciclovir MeSH
• valin škodlivé účinky   analogy a deriváty   terapeutické užití   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH
• Názvy látek
• acyklovir MeSH
• antivirové látky MeSH
• ganciklovir MeSH
• imunosupresiva MeSH
• valaciclovir MeSH
• valin MeSH